Medigen Vaccine Biologics Corporation (TPEX:6547)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
47.60
-0.90 (-1.86%)
Apr 28, 2026, 1:30 PM CST
-2.96%
Market Cap 15.94B
Revenue (ttm) 613.17M
Net Income (ttm) -281.71M
Shares Out 328.75M
EPS (ttm) -0.86
PE Ratio n/a
Forward PE 127.63
Dividend n/a
Ex-Dividend Date n/a
Volume 1,319,017
Average Volume 3,381,540
Open 48.80
Previous Close 48.50
Day's Range 47.40 - 48.80
52-Week Range 33.50 - 61.20
Beta 0.09
RSI 44.85
Earnings Date May 15, 2026

About Medigen Vaccine Biologics

Medigen Vaccine Biologics Corporation, a biotechnology drug company, engages in the research, development, and wholesale of vaccines and biopharmaceuticals, and medical devices in Taiwan. It develops enterovirus A71 vaccine, which is in Phase III clinical trial to treat enterovirus infection with severe complications; and Quadrivalent influenza vaccine, which is in Phase III clinical trial for the treatment of influenza viruses. The company also develops dengue vaccines, which has completed Phase II clinical trial to treat dengue; anti respirat... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2012
Employees 103
Stock Exchange Taipei Exchange
Ticker Symbol 6547
Full Company Profile

Financial Performance

In 2025, Medigen Vaccine Biologics's revenue was 613.17 million, an increase of 1.24% compared to the previous year's 605.64 million. Losses were -281.71 million, 250.1% more than in 2024.

Financial Statements

News

There is no news available yet.